select a format

Single User License
USD 2000 INR 128180
Site License
USD 4000 INR 256360
Corporate User License
USD 6000 INR 384540

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Wegener Polyangiitis-Pipeline Review, H1 2016

Wegener Polyangiitis-Pipeline Review, H1 2016


  • Products Id :- GMDHC8201IDB
  • |
  • Pages: 60
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Wegener Polyangiitis-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Wegener Polyangiitis-Pipeline Review, H1 2016', provides an overview of the Wegener Polyangiitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wegener Polyangiitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wegener Polyangiitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Wegener Polyangiitis

The report reviews pipeline therapeutics for Wegener Polyangiitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Wegener Polyangiitis therapeutics and enlists all their major and minor projects

The report assesses Wegener Polyangiitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Wegener Polyangiitis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Wegener Polyangiitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Wegener Polyangiitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Wegener Polyangiitis Overview 6

Therapeutics Development 7

Pipeline Products for Wegener Polyangiitis-Overview 7

Wegener Polyangiitis-Therapeutics under Development by Companies 8

Wegener Polyangiitis-Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Unknown Stage Products 12

Wegener Polyangiitis-Products under Development by Companies 13

Wegener Polyangiitis-Companies Involved in Therapeutics Development 14

Bionovis SA 14

Bristol-Myers Squibb Company 15

ChemoCentryx, Inc. 16

Coherus BioSciences, Inc. 17

Genor BioPharma Co., Ltd. 18

GlaxoSmithKline Plc 19

Panacea Biotec Limited 20

Sandoz International GmbH 21

The International Biotechnology Center (IBC) Generium 22

Wegener Polyangiitis-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

abatacept-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

belimumab-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

CCX-168-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

rituximab biosimilar-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

rituximab biosimilar-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

rituximab biosimilar-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

rituximab biosimilar-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

rituximab biosimilar-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

rituximab biosimilar-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

rituximab biosimilar-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Wegener Polyangiitis-Dormant Projects 56

Wegener Polyangiitis-Discontinued Products 57

Wegener Polyangiitis-Product Development Milestones 58

Featured News & Press Releases 58

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 58

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 59

Disclaimer 60

List of Figures

Number of Products under Development for Wegener Polyangiitis, H1 2016 7

Number of Products under Development by Companies, H1 2016 8

Comparative Analysis by Late Stage Development, H1 2016 9

Comparative Analysis by Early Stage Products, H1 2016 11

Assessment by Monotherapy Products, H1 2016 23

Number of Products by Targets, H1 2016 24

Number of Products by Stage and Targets, H1 2016 24

Number of Products by Mechanism of Actions, H1 2016 26

Number of Products by Stage and Mechanism of Actions, H1 2016 26

Number of Products by Routes of Administration, H1 2016 28

Number of Products by Stage and Routes of Administration, H1 2016 28

Number of Products by Molecule Types, H1 2016 30

Number of Products by Stage and Molecule Types, H1 2016 30

List of Tables

Number of Products under Development for Wegener Polyangiitis, H1 2016 7

Number of Products under Development by Companies, H1 2016 8

Comparative Analysis by Late Stage Development, H1 2016 9

Comparative Analysis by Clinical Stage Development, H1 2016 10

Comparative Analysis by Early Stage Development, H1 2016 11

Comparative Analysis by Unknown Stage Development, H1 2016 12

Products under Development by Companies, H1 2016 13

Wegener Polyangiitis-Pipeline by Bionovis SA, H1 2016 14

Wegener Polyangiitis-Pipeline by Bristol-Myers Squibb Company, H1 2016 15

Wegener Polyangiitis-Pipeline by ChemoCentryx, Inc., H1 2016 16

Wegener Polyangiitis-Pipeline by Coherus BioSciences, Inc., H1 2016 17

Wegener Polyangiitis-Pipeline by Genor BioPharma Co., Ltd., H1 2016 18

Wegener Polyangiitis-Pipeline by GlaxoSmithKline Plc, H1 2016 19

Wegener Polyangiitis-Pipeline by Panacea Biotec Limited, H1 2016 20

Wegener Polyangiitis-Pipeline by Sandoz International GmbH, H1 2016 21

Wegener Polyangiitis-Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 22

Assessment by Monotherapy Products, H1 2016 23

Number of Products by Stage and Target, H1 2016 25

Number of Products by Stage and Mechanism of Action, H1 2016 27

Number of Products by Stage and Route of Administration, H1 2016 29

Number of Products by Stage and Molecule Type, H1 2016 31

Wegener Polyangiitis-Dormant Projects, H1 2016 56

Wegener Polyangiitis-Discontinued Products, H1 2016 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bionovis SA

Bristol-Myers Squibb Company

ChemoCentryx, Inc.

Coherus BioSciences, Inc.

Genor BioPharma Co., Ltd.

GlaxoSmithKline Plc

Panacea Biotec Limited

Sandoz International GmbH

The International Biotechnology Center (IBC) Generium

Wegener Polyangiitis Therapeutic Products under Development, Key Players in Wegener Polyangiitis Therapeutics, Wegener Polyangiitis Pipeline Overview, Wegener Polyangiitis Pipeline, Wegener Polyangiitis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com